Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER 1 **EHR Cohort** 2

- 3
- Hanieh Razzaghi, PhD, MPH¹, Christopher B. Forrest, MD, PhD^{1,2}, Kathryn Hirabayashi, MPH¹, 4
- Qiong Wu, PhD², Andrea Allen, MS¹, Suchitra Rao, MBBS, MSCS³, Yong Chen, PhD², H. 5
- Timothy Bunnell, PhD¹⁸, Elizabeth A. Chrischilles, PhD⁴, Lindsay G. Cowell, PhD, MS⁵, Mollie 6
- R. Cummins, PhD, RN⁶, David A Hanauer, MD, MS⁷, Miranda Higginbotham, MSHA¹, 7
- Benjamin D. Horne, PhD, MStat, MPH⁸, Carol R. Horowitz, MD, MPH¹⁶, Ravi Jhaveri, MD¹², 8
- Susan Kim, MD, MMSc¹³, Aaron Mishkin, MD¹⁴, Jennifer A Muszynski, MD, MPH⁹, Susanna Naggie, MD¹⁰, Nathan M. Pajor MD, MS²⁰, Anuradha Paranjape, MD, MPH¹⁴, Hayden T Schwenk, MD, MPH¹⁵, Marion R. Sills, MD, MPH^{3,19}, Yacob G. Tedla, PhD¹⁷, David A. 9
- 10
- 11
- Williams, PhD¹¹, Charles Bailey MD, PhD^{1,2} on behalf of the RECOVER Consortium* A 12
- complete list of group members appears in the supplementary materials 13
- 14
- 15 Affiliations:
- Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA 16
- ² Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, 17
- 18 Philadelphia, PA
- ³ Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital 19
- Colorado, Aurora, CO 20
- ⁴ Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 21
- ⁵ Peter O'Donnell Jr. School of Public Health; Department of Immunology, School of 22
- Biomedical Sciences; UT Southwestern Medical Center; Dallas, TX 23
- 24 ⁶ College of Nursing, University of Utah, Salt Lake City, UT
- ⁷ Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI 25
- ⁸ Intermountain Heart Institute, Intermountain Health, Salt Lake City, UT 26
- 27 ⁹ Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital,
- Columbus, OH 28
- ¹⁰ Division of Infectious Diseases, Duke University School of Medicine; Duke Clinical Research 29
- 30 Institute, Durham, NC
- ¹¹ Department of Anesthesiology, University of Michigan, Ann Arbor, MI 31
- ¹² Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, 32
- Chicago, IL 33
- ¹³University of California, San Francisco, Division of Rheumatology, Benioff Children's 34
- Hospital, San Francisco CA 35
- ¹⁴Temple University Lewis Katz School of Medicine, Section of Infectious Diseases, 36
- 37 Philadelphia, PA
- ¹⁵Stanford School of Medicine, Division of Pediatric Infectious Diseases, Stanford, CA 38
- 39 ¹⁶Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, NYC, NY
- ¹⁷ Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 40
- Nashville, TN 41
- ¹⁸Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, DE 42
- ¹⁹OCHIN, Inc., Portland, OR 43
- ²⁰Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and 44
- University of Cincinnati College of Medicine, Cincinnati, OH 45
- Address Correspondence to: Hanieh Razzaghi, Roberts Center for Pediatric Research, Room 46
- 11361, 2716 South Street, Philadelphia, PA 19146, [razzaghih@chop.edu], (267) 425-9684 47

- 48 Short Title: Vaccine Effectiveness Against Pediatric Long COVID
- 49 Disclosures: Dr. Mollie Cummins is employed by Doxy.me Inc., a commercial telemedicine
- 50 platform provider. Dr. Benjamin Horne is a member of the advisory boards of Opsis Health and
- 51 Lab Me Analytics, and a consultant to Pfizer (regarding clinical risk scores; funds paid to
- 52 Intermountain). Dr. Susanna Naggie reports research grants from Gilead Sciences and AbbVie,
- 53 scientific advisor/stock options from Vir Biotechnologies, consulting with no financial payment
- 54 from Pardes Biosciences and Silverback Therapeutics, DSMB fees from Personal Health
- 55 Insights, Inc, event adjudication committee fees from BMS/PRA outside the submitted work. Dr.
- 56 Mishkin receives Grant support from Pfizer paid directly to Institution Advisory Board for
- 57 Takeda. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial
- stipend from Elsevier and Pediatric Infectious Diseases Society. Dr. Rao reports prior grant
- 59 support from GSK and Biofire and is a consultant for Sequiris. The remaining authors have no
- 60 disclosures.
- 61 Funding/Support: This research was funded by the National Institutes of Health (NIH)
- 62 Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery
- 63 (RECOVER) program of research.
- 64 **Disclaimer**: The views and conclusions contained in this document are those of the authors and
- should not be interpreted as representing the official policies, either expressed or implied, of theNIH.
- 67 **Abbreviations**: PCR polymerase chain reaction; EHR electronic health record; CI 95%
- 68 confidence intervals; ICD-10-CM International Classification of Diseases, version 10, clinical
- 69 modification; PMCA Pediatric Medical Complexity Algorithm; US United States of
- 70 America; VE vaccine effectiveness; VIS vaccine information system.
- 71 Article Summary: Vaccination against COVID-19 has a protective effect against long COVID
- in children and adolescents. The effect wanes over time but remains significant at 12 months.

73 What's Known on This Subject

- 74 Vaccines reduce the risk and severity of COVID-19 in children. There is evidence for reduced
- ⁷⁵ long COVID risk in adults who are vaccinated, but little information about similar effects for
- children and adolescents, who have distinct forms of long COVID.

77 What This Study Adds

- 78 Using electronic health records from US health systems, we examined large cohorts of
- vaccinated and unvaccinated patients <18 years old and show that vaccination against COVID-
- 19 is associated with reduced risk of long COVID for at least 12 months.
- 81

82 **Contributors' Statement**

- 83 Drs. Hanieh Razzaghi and Charles Bailey conceptualized and designed the study, supervised
- 84 analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.
- Drs. Christopher Forrest and Yong Chen designed the study and critically reviewed and revised
 the manuscript.
- 87 Ms. Kathryn Hirabayashi, Ms. Andrea Allen, and Dr. Qiong Wu conducted analyses, and
- critically reviewed and revised the manuscript.
- 89 Drs. Suchitra Rao, H Timothy Bunnell, Elizabeth A. Chrischilles, Lindsay G. Cowell, Mollie R.
- 90 Cummins, David A. Hanauer, Benjamin D. Horne, Carol R. Horowitz, Ravi Jhaveri, Susan Kim,
- 91 Aaron Mishkin, Jennifer A. Muszynski, Susanna Nagie, Nathan M. Pajor, Anuradha Paranjape,
- 92 Hayden T. Schwenk, Marion R. Sills, Yacob G. Tedla, David A. Williams, and Ms. Miranda Higginbotham critically ravioused and ravised the manuacrint
- 93 Higginbotham critically reviewed and revised the manuscript.
- All authors approved the final manuscript as submitted and agree to be accountable for all
- 95 aspects of the work.
- 96 **Authorship statement:** Authorship has been determined according to ICMJE recommendations.
- 97
- 98

99 Abstract

- 100 **Objective**
- 101 Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it
- 102 protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in
- 103 children aged 5-17 years.
- 104 Methods
- 105 This retrospective cohort study used data from 17 health systems in the RECOVER PCORnet
- 106 electronic health record (EHR) Program for visits between vaccine availability, and October 29,
- 107 2022. Conditional logistic regression was used to estimate VE against long COVID with
- 108 matching on age group (5-11, 12-17) and time period and adjustment for sex, ethnicity, health
- system, comorbidity burden, and pre-exposure health care utilization. We examined both
- probable (symptom-based) and diagnosed long COVID in the year following vaccination.
- 111 **Results**
- 112 The vaccination rate was 56% in the cohort of 1,037,936 children. The incidence of probable
- long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was
- 114 0.7%. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5 44.5) against
- probable long COVID and 41.7% (15.0 60.0) against diagnosed long COVID. VE was higher
- for adolescents 50.3% [36.3 61.0]) than children aged 5-11 (23.8% [4.9 39.0]). VE was
- higher at 6 months (61.4% [51.0 69.6]) but decreased to 10.6% (-26.8 37.0%) at 18-months.

118 Discussion

- 119 This large retrospective study shows a moderate protective effect of SARS-CoV-2 vaccination
- against long COVID. The effect is stronger in adolescents, who have higher risk of long
- 121 COVID, and wanes over time. Understanding VE mechanism against long COVID requires more
- study, including EHR sources and prospective data.
- 123
- 124

125 Introduction

SARS-CoV-2 has infected over 676 million people, and has been associated with 6.9 million 126 deaths¹. While severity has been lower in children than adults, statistics for the United States 127 (US) indicate >2100 deaths in children aged <21 years with COVID- 19^2 and up to 2.1% of cases 128 classified as severe disease³. Further, children may experience long-term health burdens after 129 infection, collectively referred to as post-acute sequelae of SARS-CoV-2 (PASC) or "long 130 COVID"^{4 5,6}. These may represent effects of host response to the original infection in addition 131 to or instead of direct pathogen effects⁷⁻⁹. Long COVID is heterogeneous and likely 132 underdiagnosed, but symptoms such as brain fog, dyspnea, gastrointestinal dysfunction, 133 generalized pain, and fatigue can cause significant burden for children, even after mild COVID-134 19^{4,5,10,11}. Recent research has identified specific post-acute symptoms consistent with long 135 COVID¹². Prevalence estimates vary widely^{10,12-14}. Symptoms of long COVID have been 136 reported less often and for shorter duration in children compared to adults ¹¹, and higher rates 137 have been reported for adolescents than younger children¹³. It is difficult to establish how much 138 139 this results from differential reporting of symptoms at different ages, greater difficulty distinguishing long COVID from other childhood illnesses or effects of the pandemic (e.g. 140 disruption of seasonal viral patterns, or of school progress)¹³. Despite the paucity of data about 141 long COVID in children, developing mitigation strategies is an important concern not only for 142 affected children but in societal discussions¹⁵ and for shaping public health policy¹⁶⁻¹⁸. 143

Vaccines provide the best opportunity for both reducing the risk of severe disease¹⁹⁻²⁴ as well as
short-term complications of acute infection. In adults, some reports²⁵⁻²⁹ identified a modest
benefit associated with vaccination in preventing long COVID in adults, while others did not^{30,31}.
Little data are available on the effect of vaccination on long COVID in children; in one UK study

| 148 | including 6500 children with COVID-19, no association was seen ⁴ . However, to our knowledge, |
|-----|---|
| 149 | there are no studies assessing clinical data to address this question. Efforts to learn from clinical |
| 150 | care at a large enough scale to identify underrepresented patterns provides an important |
| 151 | complement to multicenter prospective cohorts. The NIH Researching COVID to Enhance |
| 152 | Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute |
| 153 | sequelae of SARS-CoV-2 infection (PASC, or long COVID), is employing both strategies to |
| 154 | better elucidate the condition, identify effective ways to treat patients, and support families |
| 155 | impacted by long COVID. We report results from a large-scale, national collaboration of health |
| 156 | systems from the PCORnet [®] network contributing electronic health record (EHR) data as part of |
| 157 | RECOVER's real-world program ⁴⁶ . |
| 158 | Methods |
| 159 | Data sources: We conducted a retrospective cohort study based on EHR data from 41 health |
| 160 | systems for children with COVID-19, a diagnosis of acute respiratory illness, fever, dyspnea, or |
| 161 | cough, or a SARS-CoV-2 vaccine. Data, extracted quarterly, were transformed to either the |
| 162 | PCORnet (v6.0) or Observational Medical Outcomes Partnership (OMOP) (v5.3) data models, |
| 163 | and forwarded to the RECOVER-PCORnet Coordinating Center. For this study, we used the s8 |
| 164 | version of the data, collected in April 2023, which comprises 25,389,893 patients. |
| 165 | Institutional Review Board oversight was provided by the Biomedical Research Alliance of |
| 166 | New York, protocol #21-08-508-380. |
| 167 | Study Sample: Patients were eligible if they had an in-person visit between vaccine eligibility and |
| 168 | October 29, 2022, and were between 5 and <18 years at the date of vaccine eligibility. The date |
| 169 | of SARS-CoV-2 vaccine eligibility was defined as January 01, 2021, for patients aged $12 - <18$ |
| 170 | years, and October 29, 2021, for patients aged $5 - < 12$ years, corresponding to availability of |

vaccines. A small number of patients were excluded for documented COVID-19 before 28 daysafter their first vaccine dose.

| 173 | For vaccinated patients, cohort entry was the date of their first vaccine dose, while for |
|-----|--|
| 174 | unvaccinated patients, the date of an in-person visit after vaccine eligibility was selected |
| 175 | randomly, resulting in matched distribution of entry dates between cohorts. In addition, we |
| 176 | required 1 contact between 8 days and 2 years prior to cohort entry to assess baseline health |
| 177 | characteristics. To determine long COVID outcomes, we also required at least 1 in-person visit |
| 178 | between 28 and 179 days after cohort entry. |
| 179 | Outcomes: The main outcomes were diagnosed or probable long COVID. A patient had |
| 180 | diagnosed long COVID if they had two or more visits with diagnosis codes specific for long |
| 181 | COVID; a single diagnosis code classified children as having probable long COVID. In |
| 182 | addition, to account for incomplete availability or use of long-COVID-specific diagnosis codes, |
| 183 | especially for patients with early signs of long COVID, , we also classified a patient as having |
| 184 | probable long COVID if they had COVID-19 (SARS-CoV-2 PCR or antigen positive or |
| 185 | COVID-19-specific diagnosis codes) plus at least two long-COVID-compatible diagnoses 28- |

186 179 days after infection. These diagnoses were identified in prior work as post-acute associations

187 with COVID- $19^{12,32}$ (Supplemental Table S3).

Some results are reported for pre-omicron and omicron eras. This applies only to adolescents, as vaccines for younger children were not available substantially before the omicron era. To maintain consistency across analyses, November 29, 2021, the first day a younger child could have had a qualifying post-vaccine infection, was used as the dividing line between eras; at that point omicron was circulating in the US, and became the dominant strain a few weeks later. For each patient, the date of a SARS-CoV-2 infection following cohort entry, if one occurred,

194 was used to place their results in either of the two eras; if the patient never developed COVID-195 19, the date of cohort entry was used.

196 *Exposure:* The primary exposure was receipt of at least one dose of SARS-CoV-2 vaccine. Vaccine doses were ascertained using a vaccine code (CVX or RxNorm) designating an 197 198 administered or patient-reported dose, a procedure code indicating SARS-CoV-2 vaccination, or a vaccine description containing the string "COVID" or "SARS". Where available, data was 199 200 retrieved from state/regional vaccine information systems via hospital operational procedures. 201 Adequate vaccine data capture was defined as a site-reported vaccination rate at least 60% of the CDC-estimated rate² for its coverage area, based on addresses of patients seen during the 202 203 pandemic. Where dose counts were used, all recorded doses within 14 days of a base dose were considered a single dose. 204

205 *Demographic and clinical data*. Age, sex, and ethnicity were taken from EHRs. Comorbidity

data used the body system taxonomy of the Pediatric Medical Complexity Algorithm $(PMCA)^{14}$.

Diagnoses received up to 3 years before cohort entry were considered. To classify patients as complex-chronic, chronic, or no chronic condition, the "more conservative" version of the algorithm was applied.

Main analysis. We matched vaccinated and unvaccinated patients on age group at cohort
entry (5-11, 12-17) and time period (six-month cohort entry period). We limited long COVID
observations to 12 months following cohort entry to account for waning of vaccine effectiveness
(VE) over time.

Sensitivity analyses: To evaluate potential impact of attrition due to matching, we
performed a sensitivity analysis using inverse probability of treatment weighting that
incorporated age group, time of cohort entry, sex, ethnicity, health system, number of baseline

| 217 | visits to the health system, PMCA-defined body system(s) affected by chronic illness, |
|-----|--|
| 218 | progressive disease, and malignancy. Further, we estimated VE after changing the window for |
| 219 | outcomes to 6 months and 18 months post cohort entry and restricting the vaccinated cohort to |
| 220 | those with at least 2 recorded doses. |
| 221 | Cohort Comparison. For unadjusted analyses, follow-up time was computed from cohort |
| 222 | entry until the end of observation. We calculated an incidence rate ratio (IRR) comparing |
| 223 | vaccinated to unvaccinated groups and derived 95% CIs using the estimation of Wald ³³ . |
| 224 | Corresponding VE was computed as $100 \times (1 \text{ IRR})$. |
| 225 | For adjusted analyses, we used conditional logistic regression to account for stratification. |
| 226 | Covariates included sex, ethnicity, health system, baseline utilization (0, 1-5, 6-10, 11-24, 25-49, |
| 227 | 50-99, or 100+ encounters in the 3 years prior to cohort entry), the number of PMCA body |
| 228 | systems affected, and the presence of progressive or malignant condition. Since the prevalence of |
| 229 | long COVID was low, IRR \approx OR, so the corresponding VE was computed as $100 \times (1 - OR)$. |
| 230 | Mediation Analyses. To understand the direct and indirect impact of vaccination on long |
| 231 | COVID, we conducted causal mediation analyses, where the treatment was pre-infection |
| 232 | vaccination, the mediator was SARS-CoV-2 infection, and the outcome was long COVID. We fit |
| 233 | two logistic regression models, the first of treatment on the mediator, and the second of treatment |
| 234 | and mediator on the outcome, adjusting for the same set of covariates. From these models, we |
| 235 | estimated the effect and CIs of vaccination on long COVID independent of infection, and of |
| 236 | vaccination on long COVID mediated by infection. |
| 237 | Statistical Tools. Data analysis was performed using R ¹⁷ version 4.0.2. Exact matching |
| 238 | used the matchIt package ³⁴ version 4.4.0, while IPTW were computed via twang ³⁵ version |

239 2.5. Conditional logistic regression used the clogit() algorithm implemented in the 240 survival package ³⁶ version 3.5. Significant effects were identified based on a threshold of 241 a < 0.05.

242 **Results**

243 Study Cohort

Immunization data from 17 health systems was sufficiently robust for inclusion. Cohort

formation is described in Figure 1: the 5–11-year-old group comprised 480,498 children, while

the 12-17 year-old group comprised 719,519 children/adolescents. Overall, 55% received at

least one SARS-CoV-2 vaccine, and 84% of vaccinated children received two or more doses.

248 Compared to unvaccinated children, vaccinated patients were older, had lower baseline

249 healthcare utilization, and fewer chronic conditions. Girls and children who identified as Asian

or Hispanic were more common in the vaccinated group, while those identifying as Black and

251 White were less common (Table 1). Descriptive statistics for the matched cohorts are provided in

252 Supplemental Table S1. Vaccinated patients had slightly fewer comorbidities and healthcare

utilization than unvaccinated patients. The prevalence of probable long COVID was 0.3% in the

cohort overall; for children with COVID-19 after cohort entry, prevalence of diagnosed long

255 COVID was 0.8%, and adding probable cases raised the prevalence of long COVID to 4.5%.

256 Effect of Vaccination on long COVID in Children and Adolescents

While the likelihood that a recorded vaccine is incorrectly attributed to a patient is very low, the risk that dose count is incomplete in reported data is well-described³⁷, and discontinuation before a second dose is uncommon. It is therefore more accurate in this study design to include patients with evidence of vaccination, and, because any compensatory bias introduced thereby will tend to reduce estimates, more responsible to report results that do not overestimate vaccine

262 effectiveness. We analyzed all children with evidence of vaccination prior to SARS-CoV-2 263 infection. Results were very similar across approaches: VE was 35% (95% CI 24–45%) for the 264 combined age groups (Table 2), with greater effect in adolescents than younger children. For 265 children known to be completely vaccinated (*i.e.* 2+ doses) prior to SARS-CoV-2 infection, VE was 35% (95% CI 35– 53%) against probable long COVID within 12 months (Figure 2), with 266 consistent findings within age strata, supporting the validity of our approach. For comparison, 267 VE estimates against SARS-CoV-2 infection are shown in Supplemental Figure S1. We 268 269 observed decreased likelihood of long COVID among boys and children with non-Hispanic 270 Black or Asian ethnicity (Supplementary Table S2). The presence of chronic conditions had minimal effect, though likelihood of long COVID rose with increasing baseline utilization. 271 The protective effect of vaccination appeared to wane over time. We observed higher VE 272 273 against long COVID within 6 months of vaccination than 12 months, while extending the 274 observation period to 18 months revealed a further diminution (Figure 3). Protection was also 275 seen in children who started vaccination after recuperating from COVID-19 (Supplemental 276 Figure S2). 277 One-to-one matching resulted in loss of 27% of unvaccinated and 64% of vaccinated patients due

to the high overall vaccination rate. To assess the effect of this on our VE estimates, we used IPTW to adjust for multiple potential confounders without decreasing cohort size. Once again, a protective effect was seen, though with a smaller magnitude of 24% (95% CI 20 – 28%) for vaccination on long COVID up to a year later (Supplemental Figure S3).

To assess where in the path to long COVID the vaccine might have impact, we performed mediation analysis, estimating effect of vaccine on long COVID via change in COVID-19 risk (indirect effect) separately from other effects on long COVID (direct effect). For 5–11-year-

285 olds, who became vaccine eligible just before the omicron variant became prevalent, the long 286 COVID-associated OR for indirect effect on probable long COVID was 0.67 (95% CI 0.64 – 0.70), while for direct effect the OR was 1.34 (95% CI 1.13 – 1.59). For adolescents, results 287 288 were similar: in the pre-omicron era the indirect effect OR was 0.46 (95% CI 0.45 - 0.48) and direct effect OR was 1.32 (95% CI 1.12 – 1.55); in the omicron era, the analogous ORs were 289 0.45 (95% CI 0.41 - 0.49) and 0.99 (95% CI 0.73 - 1.34). These results suggest that throughout 290 291 the period of pediatric use, the effectiveness of vaccine against long COVID is closely tied to its effectiveness against the antecedent COVID-19 episode. 292

293 Discussion

To our knowledge, this national-scale study, with a diverse cohort of over 1 million children, is 294 295 the first to estimate the VE against long COVID in children. Our findings suggest that SARS-CoV-2 vaccine is associated with reduced risk of Long COVID in children and adolescents. The 296 protective effect was greater among adolescents than younger children, reflecting activity against 297 298 delta and omicron strains, while use for younger children is limited to the omicron era. Since diagnostic codes for long COVID (e.g. ICD-10-CM U09.9) are rare in children, we have 299 300 examined both specific diagnosis as an outcome, and a broader definition based on the repeated 301 presence from 1-6 months after infection of symptoms that occur more frequently following COVID-19 than in uninfected children 12,32 . The effect of vaccine is similar for both outcomes 302 303 and is also seen in children vaccinated after an initial episode of COVID-19, suggesting that 304 vaccination confers some benefit against future late effects. Mediation analysis suggests that the protective effect of vaccination may be primarily via reduction in the occurrence or severity of 305 306 infection.

307 Our finding of a protective effect against long COVID in children are consistent with those 308 observed in adults, while the VE estimates in our study are lower than studies assessing the short-term effect of vaccines in the one week to one month after vaccination²⁹. Other reasons are 309 310 varied definitions of long COVID between these studies, and different methodological approaches. Our observed higher VE for adolescents is similar to studies examining acute 311 infection ³⁸. Further analyses are required to explore whether other factors contribute to this 312 difference, such as long COVID symptoms being more frequently reported or documented in 313 adolescents. 314

Waning effects of vaccine against long COVID are to be expected ³⁹, similar to studies against 315 acute infection ^{40 41 42}. The reasons include reduced neutralization efficiency against newer 316 strains and waning of pre-existing antibodies over time⁴³. It is also possible that long COVID 317 318 starting several months after acute infection, or delayed diagnosis or recognition of long COVID, 319 may contribute to this phenomenon. Further, waning effect may reflect the impact of successive infections rather than late-onset long COVID. This is difficult to assess analytically, given fewer 320 321 COVID-19 episodes are being documented in the EHR during the omicron era. Evaluations of VE over time are needed to address whether these waning effects can be overcome through 322 booster or annual vaccine doses. 323

VE studies using EHR data rely on accurate capture of clinical and vaccine data, with adjustment for important confounders to minimize potential bias ^{44 45}. Our focus on data quality, including comparison to the CDC's county-level vaccination data, reduced our cohort size but yielded more reliable vaccination data. Our assessment of VE against acute SARS-CoV-2 was similar to VE estimates from other pediatric studies, further validating our findings and approach. Finally,

we performed matching on age and time period to limit secular effects and conducted sensitivityanalyses including inverse probability of treatment weighting, with similar findings.

331 Nonetheless, several challenges exist with the identification of long COVID in children using

EHR data, which may confound assessment of our outcome. There has been low uptake of the

long COVID (ICD10-CM U09.9) diagnosis code in pediatrics; it is more often seen in older

children and associated with respiratory, cardiovascular, or fatigue subtypes of long COVID 32 .

For this reason, we supplemented our outcome definition with a symptom-based computable

phenotype definition of long COVID we have developed, which includes features related to long

337 COVID based on statistical association and chart review validation^{12,32}. However, long COVID

338 presentations are heterogeneous, and symptoms and conditions may overlap with other childhood

339 illnesses, with the potential for misclassification of long COVID in our study. These limitations

340 on classification accuracy are expected to affect both vaccinated and unvaccinated cohorts,

similarly, so would not confound the comparison of the two.

342 There are other limitations that warrant discussion. First, our study relies on secondary use of 343 EHR data, and is subject to bias due to differential access to and utilization of healthcare during the pandemic, as well as clinical practice variation across sites. We required both pre- and post-344 345 vaccine visits to establish a baseline of utilization, which may create bias toward sicker patients, 346 but importantly we did not observe major imbalances in utilization rates between cohorts. Next, testing practices changed over time, with an increased reliance on home antigen testing in later 347 phases of the pandemic, potentially leading to misclassification of symptom based long COVID. 348 In addition, a large proportion of patients in our data with a long COVID diagnosis code do not 349 have documentation in the EHR of the antecedent COVID-19 episode, which prevented use of 350 351 severity as an adjustment to vaccine effect.

352 Conclusion

- 353 Our results provide substantial evidence in a large and diverse cohort of children receiving health
- care for protective effect in children 5 years and older. This study adds to the growing body of
- knowledge about mitigating effect of vaccines on COVID-19, while demonstrating the need for
- further research utilizing a range of designs to examine the protective effect of these vaccines
- against subsequent strains and to help guide vaccine policy.

358 Acknowledgments

359

We are grateful to the health systems, clinicians, and patients at member sites without whose trust research of this type would not be possible. We are also grateful to clinical data teams at each RECOVER site involved in data extraction and integration, as well as colleagues at the RECOVER Coordinating Center, particularly Susan Hague, for maintaining the RECOVER data infrastructure. Additionally, we would like to thank the National Community Engagement Group (NCEG), all patient, caregiver and community Representatives, and all the participants enrolled in the RECOVER Initiative

367

368 **References**

Johns Hopkins University. COVID-19 dashboard by the Center for Systems Science and
 Engineering (CSSE) at Johns Hopkins University (JHU). Accessed March 04, 2023.

- 371 https://coronavirus.jhu.edu/map.html
- 372 2. Centers for Disease Control and Prevention (CDC). CDC COVID Data Tracker.
- Accessed March 04, 2023. <u>https://covid.cdc.gov/covid-data-tracker/#demographics</u>
- 374 3. Forrest CB, Burrows EK, Mejias A, et al. Severity of Acute COVID-19 in Children <18
- Years Old March 2020 to December 2021. *Pediatrics*. Apr 1 2022;149(4)doi:10.1542/peds.2021055765
- 4. Pinto Pereira SM, Nugawela MD, Rojas NK, et al. Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people. *Arch Dis Child*. Apr
- 379 2023;108(4):289-295. doi:10.1136/archdischild-2022-324656
- 5. Trapani G, Verlato G, Bertino E, et al. Long COVID-19 in children: an Italian cohort
- 381 study. *Ital J Pediatr.* Jun 3 2022;48(1):83. doi:10.1186/s13052-022-01282-x
- 382 6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,
- mechanisms and recommendations. *Nat Rev Microbiol*. Mar 2023;21(3):133-146.
- 384 doi:10.1038/s41579-022-00846-2
- Kuczborska K, Buda P, Ksiazyk J. Long-COVID in immunocompromised children. *Eur J Pediatr.* Sep 2022;181(9):3501-3509. doi:10.1007/s00431-022-04561-1
- 8. Pierce CA, Herold KC, Herold BC, et al. COVID-19 and children. *Science*. Sep 9
- 388 2022;377(6611):1144-1149. doi:10.1126/science.ade1675
- 389 9. Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem
- inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19:

- optimizing definition and management. *Pediatr Res.* May 2023;93(6):1499-1508.
- 392 doi:10.1038/s41390-022-02263-w
- 10. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19
- outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health*. Jun
 2021;5(6):e22-e23. doi:10.1016/S2352-4642(21)00124-3
- 11. Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild
- 397 SARS-CoV-2 infection: nationwide cohort study. *BMJ*. Jan 11 2023;380:e072529.
- 398 doi:10.1136/bmj-2022-072529
- 12. Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of
- 400 SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. Aug 22
- 401 2022;doi:10.1001/jamapediatrics.2022.2800
- 402 13. Adler L, Israel M, Yehoshua I, et al. Long COVID symptoms in Israeli children with and
- 403 without a history of SARS-CoV-2 infection: a cross-sectional study. BMJ Open. Feb 21
- 404 2023;13(2):e064155. doi:10.1136/bmjopen-2022-064155
- 405 14. Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 Conditions Among Children
- 406 90 Days After SARS-CoV-2 Infection. JAMA Netw Open. Jul 1 2022;5(7):e2223253.
- 407 doi:10.1001/jamanetworkopen.2022.23253
- 408 15. Katika A, Zoulias E, Koufi V, Malamateniou F. Mining Greek Tweets on Long COVID
- 409 Using Sentiment Analysis and Topic Modeling. Stud Health Technol Inform. Jun 29
- 410 2023;305:545-548. doi:10.3233/SHTI230554
- 411 16. Kasi SG, Dhir SK, Shah A, et al. Coronavirus Disease 2019 (COVID-19) Vaccination for
- 412 Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on
- 413 Vaccination and Immunization Practices. *Indian Pediatr.* Jan 15 2022;59(1):51-57.
- 414 doi:10.1007/s13312-022-2421-9
- 415 17. Barie PS, Brindle ME, Khadaroo RG, Klassen TL, Huston JM. Omicron, Long-COVID, 416 and the Safety of Elective Surgery for Adults and Children: Joint Guidenee from the
- 416 and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the
- 417 Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery
- Strategic Clinical Network, Alberta Health Services. *Surg Infect (Larchmt)*. Feb 2023;24(1):618. doi:10.1089/sur.2022.274
- 420 18. Paul S, Mishra CM. Do we need to vaccinate every child against COVID-19: What
- 421 evidence suggests-A systematic review of opinions. *Front Public Health*. 2022;10:1002992.
 422 doi:10.3389/fpubh.2022.1002992
- 423 19. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
- 424 CoV-2 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 425 20. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2
- 426 Vaccine at Completion of Blinded Phase. *N Engl J Med.* Nov 4 2021;385(19):1774-1785.
- 427 doi:10.1056/NEJMoa2113017
- 428 21. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2
- mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med.* Nov 4 2021;385(19):1761-1773.
 doi:10.1056/NEJMoa2110345
- 431 22. Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2,
- and vaccine effectiveness associated with the Delta variant. *Science*. Dec 17
- 433 2021;374(6574):eabl9551. doi:10.1126/science.abl9551
- 434 23. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2
- 435 Vaccines against Omicron Variant in South Africa. N Engl J Med. Jun 9 2022;386(23):2243-
- 436 2245. doi:10.1056/NEJMc2202061

- 437 24. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
- 438 CoV-2 Omicron and Delta variants. *Nat Med.* May 2022;28(5):1063-1071. doi:10.1038/s41591439 022-01753-y
- 440 25. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat* 441 *Med.* Jul 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0
- 442 26. Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination
- in an EHR-based cohort study from the RECOVER program. *Nat Commun*. May 22
- 444 2023;14(1):2914. doi:10.1038/s41467-023-38388-7
- 445 27. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2
- 446 infection: A retrospective cohort study of 10,024 breakthrough infections. *Brain Behav Immun.*447 Jul 2022;103:154-162. doi:10.1016/j.bbi.2022.04.013
- 448 28. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms
- 449 after covid-19 vaccination: community based cohort study. *BMJ*. May 18 2022;377:e069676.
 450 doi:10.1136/bmj-2021-069676
- 451 29. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk
- 452 of developing long-COVID and on existing long-COVID symptoms: A systematic review.
- 453 EClinicalMedicine. Nov 2022;53:101624. doi:10.1016/j.eclinm.2022.101624
- 454 30. Arjun MC, Singh AK, Pal D, et al. Characteristics and predictors of Long COVID among
- 455 diagnosed cases of COVID-19. *PLoS One*. 2022;17(12):e0278825.
- 456 doi:10.1371/journal.pone.0278825
- 457 31. Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-
- 458 acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. Jul 30
- 459 2022;40(32):4424-4431. doi:10.1016/j.vaccine.2022.05.090
- 460 32. Lorman V, Rao S, Jhaveri R, et al. Understanding pediatric long COVID using a tree-
- 461 based scan statistic approach: an EHR-based cohort study from the RECOVER Program. JAMIA
 462 Open. Apr 2023;6(1):00ad016. doi:10.1093/jamiaopen/00ad016
- 33. Sahai H, Khurshid A. Statistics in epidemiology : methods, techniques, and applications.
 464 CRC Press; 1996:321 p.
- 465 34. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric 466 Causal Inference. *Journal of Statistical Software*. 06/14 2011;42(8):1 - 28.
- 467 doi:10.18637/jss.v042.i08
- 468 35. Ridgeway GM, D. F.; Morral, A. R.; Cefalu, M.; Burgette, L. F.; Pane, J. D.; Griffin, B.
- 469 A. Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the R TWANG A70 Package 2022
- 470 *Package*. 2022.
- 471 36. Therneau TM. A Package for Survival Analysis in R. Accessed 2023-08-07, 2023.
- 472 37. Centers for Diseease Control and Prevention Data (CDC). Definitions for COVID-19
- 473 Vaccinations in the United States. Accessed August 25, 2022.
- 474 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/reporting-
- 475 vaccinations.html#anchor_1649867074684
- 476 38. Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer
- 477 BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11
- 478 Years and Adolescents Aged 12-15 Years PROTECT Cohort, July 2021-February 2022.
- 479 *MMWR Morb Mortal Wkly Rep.* Mar 18 2022;71(11):422-428. doi:10.15585/mmwr.mm7111e1
- 480 39. Yewdell JW. Individuals cannot rely on COVID-19 herd immunity: Durable immunity to
- 481 viral disease is limited to viruses with obligate viremic spread. *PLoS Pathog*. Apr
- 482 2021;17(4):e1009509. doi:10.1371/journal.ppat.1009509

- 483 40. Klein NP, Demarco M, Fleming-Dutra KE, et al. Effectiveness of BNT162b2 COVID-19
- Vaccination in Children and Adolescents. *Pediatrics*. May 1 2023;151(5)doi:10.1542/peds.2022060894
- 486 41. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron
- 487 Variant in Children and Adolescents. *N Engl J Med.* May 19 2022;386(20):1899-1909.
- 488 doi:10.1056/NEJMoa2202826
- 489 42. Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2
- 490 Vaccine against Omicron in Children 5 to 11 Years of Age. N Engl J Med. Aug 11
- 491 2022;387(6):525-532. doi:10.1056/NEJMoa2203209
- 492 43. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2
- breakthrough infections in vaccinated individuals: measurement, causes and impact. *Nat Rev Immunol.* Jan 2022;22(1):57-65. doi:10.1038/s41577-021-00662-4
- 495 44. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative
- 496 Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol*. Sep 1
- 497 2016;184(5):345-53. doi:10.1093/aje/kww064
- 498 45. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for
- 499 causality: lessons from vaccine effectiveness and impact studies. *Int J Epidemiol*. Dec 1
- 500 2016;45(6):2060-2074. doi:10.1093/ije/dyw124
- 46. *RECOVER:* Researching COVID to Enhance Recovery. (n.d.). RECOVER: Researching
- 502 COVID to Enhance Recovery. https://recovercovid.org/
- 503
- 504 **Table 1.** <u>Cohort Description for Full Cohort</u>

| | Vaccinated (N = 692912) | Unvaccinated (N = 345024) | Overall (N = 1037936) | |
|------------------------------------|----------------------------|------------------------------|---------------------------------|--|
| Race/Ethnicity | | | | |
| Asian | 45267 (6.5%) | 8380 (2.4%) | 53647 (5.2%) | |
| Black/AA (non-Hispanic) | 84642 (12.2%) | 63183 (18.3%) | 147825 (14.2%) | |
| Hispanic | 168102 (24.3%) | 70976 (20.6%) | 239078 (23.0%) | |
| Multiple/Other/ Missing/Unknown | 91494 (13.2%) | 36674 (10.6%) | 128168 (12.3%) | |
| White (non-Hispanic) | 303407 (43.8%) | 165811 (48.1%) | 469218 (45.2%) | |
| Age (yr) at Entry ^a | | | | |
| Mean (SD) | 12.4 (3.58) | 11.1 (3.66) | 11.9 (3.65) | |
| Median [Min, Max] | 12.8 [5.02, 18.0] | 11.0 [5.01, 18.0] | 12.2 [5.01, 18.0] | |
| Age Group at Entry ^a | | | | |
| 5-11 years | 279279 (40.3%) | 201019 (58.3%) | 480298 (46.3%) | |
| 12-17 years | 413633 (59.7%) | 144005 (41.7%) | 557638 (53.7%) | |
| Sex | | | | |
| Female/Missing | 353971 (51.1%) | 168787 (48.9%) | 522758 (50.4%) | |
| Male | 338941 (48.9%) | 176237 (51.1%) | 515178 (49.6%) | |

| | Vaccinated (N = 692912) | Unvaccinated (N = 345024) | Overall (N = 1037936) |
|---|----------------------------|------------------------------|--------------------------|
| Time Period of Entry ^a | | | |
| Dec 2020 – May 2021 | 197799 (28.5%) | 38763 (11.2%) | 236562 (22.8%) |
| Jun – Nov 2021 | 319605 (46.1%) | 65391 (19.0%) | 384996 (37.1%) |
| Dec 2021 – May 2022 | 157720 (22.8%) | 135878 (39.4%) | 293598 (28.3%) |
| Jun – Nov 2022 | 17788 (2.6%) | 104992 (30.4%) | 122780 (11.8%) |
| In-Person Visits in | | | |
| Baseline Period | | | |
| 00 visits ^b | 44741 (6.5%) | 12236 (3.5%) | 56977 (5.5%) |
| 01 to 05 visits | 261683 (37.8%) | 122599 (35.5%) | 384282 (37.0%) |
| 06 to 10 visits | 168774 (24.4%) | 90751 (26.3%) | 259525 (25.0%) |
| 11 to 24 visits | 149470 (21.6%) | 83087 (24.1%) | 232557 (22.4%) |
| \geq 25 visits | 68244 (9.9%) | 36351 (10.5%) | 104595 (10.1%) |
| Chronic Disease Category ^c | | | |
| Non-complex Chronic | 63877 (9.2%) | 33448 (9.7%) | 97325 (9.4%) |
| Complex Chronic | 20983 (3.0%) | 12903 (3.7%) | 33886 (3.3%) |
| None | 608052 (87.8%) | 298673 (86.6%) | 906725 (87.4%) |
| Progressive Condition ^c | | | |
| No | 654097 (94.4%) | 321720 (93.2%) | 975817 (94.0%) |
| Yes | 38815 (5.6%) | 23304 (6.8%) | 62119 (6.0%) |
| Malignancy^c | | | |
| No | 687759 (99.3%) | 341609 (99.0%) | 1029368 (99.2%) |
| Yes | 5153 (0.7%) | 3415 (1.0%) | 8568 (0.8%) |
| Institution | | | |
| А | 23144 (3.3%) | 14769 (4.3%) | 37913 (3.7%) |
| В | 65697 (9.5%) | 29160 (8.5%) | 94857 (9.1%) |
| С | 142143 (20.5%) | 43523 (12.6%) | 185666 (17.9%) |
| D | 65036 (9.4%) | 46009 (13.3%) | 111045 (10.7%) |
| E | 15003 (2.2%) | 3495 (1.0%) | 18498 (1.8%) |
| F | 109402 (15.8%) | 55253 (16.0%) | 164655 (15.9%) |
| G | 17214 (2.5%) | 2057 (0.6%) | 19271 (1.9%) |
| Н | Н 335 (0.0%) | | 2031 (0.2%) |
| Ι | 47910 (6.9%) | 33443 (9.7%) | 81353 (7.8%) |
| J | 26925 (3.9%) | 12387 (3.6%) | 39312 (3.8%) |
| K | 45811 (6.6%) | 17818 (5.2%) | 63629 (6.1%) |
| L | 39651 (5.7%) | 42678 (12.4%) | 82329 (7.9%) |
| М | 14732 (2.1%) | 11696 (3.4%) | 26428 (2.5%) |
| N | 2416 (0.3%) | 1371 (0.4%) | 3787 (0.4%) |
| 0 | 13352 (1.9%) | 6928 (2.0%) | 20280 (2.0%) |

| | Vaccinated (N = 692912) | Unvaccinated (N = 345024) | Overall (N = 1037936) |
|---|----------------------------|------------------------------|--------------------------|
| Р | 23249 (3.4%) | 7076 (2.1%) | 30325 (2.9%) |
| Q | 14418 (2.1%) | 8021 (2.3%) | 22439 (2.2%) |
| R | 26474 (3.8%) | 7644 (2.2%) | 34118 (3.3%) |

^a Vaccination date or visit date if unvaccinated

- ^c Based on PMCA
- 508

509 Table 2. <u>SARS-CoV-2 Vaccine Effectiveness Against Long COVID</u>

510

| | | Vaccine Effectiveness (%), 95% CI | |
|-----------------------|---------------------------|-----------------------------------|-----------------------|
| | $\mathbf{N}^{\mathbf{a}}$ | Unadjusted | Adjusted ^b |
| Symptom-based or | | | |
| Diagnosed long COVID | | | |
| Child (5-11 y), | 753 | 19.7 (7.1 – 30.6) | 23.8 (4.9 - 39.0) |
| omicron | | | |
| Adolescent (12-17 y), | 961 | 28.7 (18.8 - 37.4) | 50.3 (36.6 - 61.0) |
| all patients | | | |
| Adolescent (12-17 y), | 726 | | 35.3 (4.8 - 56.0) |
| pre-omicron | | | |
| Adolescent (12-17y), | | | 58.7 (39.1 – 72.0) |
| omicron | | | |
| All ages (5-17 y) | 1,669 | 25.3 (17.6 - 32.2) | 35.4 (24.5 - 44.5) |
| Diagnosed long COVID | | | |
| only | | | |
| Child (5-11 y) | 82 | 16 (-32.7 – 46.9) | 48.2 (21 – 77.8) |
| Adolescent (12-17 y) | 194 | 41.7 (21.4 - 57.0) | 56.1 (25.8 - 74.0) |
| | | | |
| | | | |
| All ages (5-17 y) | 270 | 35.6 (17.4 - 50.0) | 41.7 (15.0 - 60.0) |

^a Cases of long COVID. Note that values for 5-11 and 12-17 year age strata do not sum to the value for 5-17 as each stratum is drawn from sites with usable vaccine data for all ages in that stratum.

^b Adjusted for sex, ethnicity, health system, baseline utilization in the 3 years prior to cohort entry, the

514 number of body systems affected in the same interval, and the presence of a condition defined in the

515 PMCA as either progressive or malignant

- 516
- 517
- 518
- 519
- 520
- 521

^b Patients with baseline eligibility data based on administrative (*e.g.* telephone) visits

- 522 **Figure 1:** <u>Study Sample Selection</u>. Steps in the construction of the overall study sample are
- shown, including demographic and vaccine-related eligibility criteria. At each step, the number
- of children satisfying all criteria to that point is shown, as is the percentage of children in the
- previous step who were retained. ^a Vaccination rates \geq 70% of CDC regional estimate
- 526 Figure 2. <u>Vaccine effectiveness estimates for children receiving at least 2 doses of mRNA</u>
- 527 <u>vaccine in their primary series</u>. Analyses were otherwise structured identically to the main
- 528 analysis.
- 529 Figure 3. Durability of vaccine effectiveness of SARS-CoV-2 vaccine against long COVID.
- Results are shown for PASC occurring within 6, 12, or 18 months of vaccination.







Outcome and Cohort